Apr. 15, 2024
WuXi Biologics Selected for S&P Global Sustainability Yearbook 2024
WuXi Biologics
Offering End-to-End Solutions
Services
& Solutions
A global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics.
Technologies
Technology platforms that span the entire drug discovery to manufacturing spectrum.
WuXi XDC
A WuXi Biologics subsidiary, greatly simplifies bioconjugate development and manufacturing.
Mammalian
Unparalleled capacities and expertise for the discovery, development and cGMP manufacture of biologics from concept to commercialization.
Testing
Providing extensive expertise and high-quality biosafety testing under EMA, ISO (CNAS) and CMA certified laboratories.
Microbial
E. coli and yeast based expression systems, process development and cGMP manufacturing platform
Quality
World-class quality systems approved by the U.S. FDA, EMA and NMPA.
Viral
Viral vector based vaccine and therapeutic virus development and cGMP manufacturing platform.
Locations
Total estimated capacity for biopharmaceutical production in China, Ireland, the U.S., Germany and Singapore to exceed 580,000 liters by 2026.
United States
Ireland
Germany
Singapore
China
